Clik here to view.
Takeda Completes Sale of Select OTC and Non-Core Assets to STADA
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to STADA...
View ArticleClik here to view.
武田收到CHMP同意ALUNBRIG® (brigatinib)用于ALK+非小细胞肺癌一线治疗的肯定意见
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited)(TSE:4502/NYSE:TAK)今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)接纳了一项肯定意见，推荐核准ALUNBRIG...
View ArticleClik here to view.
武田薬品、ALK陽性非小細胞肺がんのファーストライン治療薬としてのALUNBRIG®（ブリガチニブ）に対するCHMPの肯定的見解を受領
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
拓臻生物将在2020亚太肝脏研究学会年会上发表其候选药物 SSAO激动剂TERN-201临床Ⅰ期研究数据
美国加州福斯特城与中国上海 Terns Pharmaceuticals 拓臻生物 —...
View ArticleClik here to view.
Terns Pharmaceuticals to Present Data from an Ongoing Phase 1 Clinical Trial...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis...
View ArticleClik here to view.
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for...
NEW YORK & CAMBRIDGE, Mass. & ROTTERDAM, Netherlands & SUZHOU, China Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to...
View ArticleClik here to view.
Terns PharmaceuticalsがNASH治療薬として開発中のSSAO阻害薬TERN-201の進行中の第1相臨床試験データを発表へ
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleClik here to view.
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition...
View ArticleClik here to view.
武田提供3期TOURMALINE-MM2试验的更新
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天发布了TOURMALINE-MM2研究的结果，该研究旨在评估不适合移植的多发性骨髓瘤新诊断患者在来那度胺和地塞米松基础上添加NINLARO™...
View ArticleClik here to view.
Clik here to view.
Sumitomo Heavy Industries, Ltd. Obtains Medical Device Approval for...
TOKYO Sumitomo Heavy Industries, Ltd. (TOKYO:6302)(President: Shinji Shimomura, referred as SHI hereinafter) has performed clinical trial of the BNCT*1) (Boron Neutron Capture Therapy) system using...
View ArticleClik here to view.
Harbour BioMed Raises $75 Million Series B+ Venture Capital Financing to...
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SUZHOU, China Harbour BioMed (HBM) today announced successful completion of its Series B+ round financing of $75 million to accelerate the...
View ArticleClik here to view.
Tyligand Bioscience and Context Therapeutics Sign Strategic Development...
SHANGHAI & PHILADELPHIA Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on...
View ArticleClik here to view.
Genetron Health Responds to Wuhan Huoshenshan Hospital’s Request with...
BEIJING In urgent response to Wuhan Huoshenshan Hospital’s request for more accurate, rapid and comprehensive diagnostic platform, Genetron Holdings Limited (“Genetron Health”), a China-based...
View ArticleClik here to view.
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA®...
TEL AVIV, Israel & PARSIPPANY, N.J. & INCHEON, South Korea Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Celltrion...
View ArticleClik here to view.
Propanc Biopharma’s Scientific Advisory Board Member Promoted to...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Hansoh Pharma’s AMEILE (almonertinib) Receives Marketing Authorization in...
SHANGHAI Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, announced that the National Medical Products Administration (NMPA) has granted...
View ArticleClik here to view.
Tarveda Therapeutics and SciClone Pharmaceuticals International Establish...
WATERTOWN, Mass. Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as...
View ArticleClik here to view.
Genomics Company Lucence Develops Viral Sample Collection Medical Device for...
SINGAPORE Molecular diagnostics company Lucence announced today the development of the SAFER-Sample (Stabilization of nucleic Acid Formulation for Evaluation of RNA) kit, a sample collection medical...
View ArticleClik here to view.
Genetron Health Contributes to China’s First Expert Consensus Statement on...
BEIJING The “Beijing Expert Consensus Statement on the Standardized Application of Next-Generation Sequencing Technology in Clinical Tests – Tumor (1st Edition)” has been officially published in...
View Article